Sensorion announces appointment of John Furey, former COO of Spark Therapeutics, as independent board member. pdfRead

Sensorion: reporting of the General Assembly - Appointment of three new directors. pdfRead

Sensorion receives FDA IND approval for Arazasetron (SENS-401). pdfRead

Sensorion announces an oral presentation at the 5th congress of European ORL-Head & Neck Surgery in Brussels. pdfRead

Sensorion receives European Medicines Agency agreement on the Pediatric Investigation Plan (PIP) for Arazasetron  (SENS-401) in two indications. pdfRead


20200910 pipeline


Patient center

Corporate presentation